AmerisourceBergen unit to plead guilty in U.S. in $260 million settlement

(Reuters) – An AmerisourceBergen Corp unit will plead guilty on Wednesday to a misdemeanor and pay $260 million to resolve a U.S. probe into a pre-filled syringe program operated by a unit of the company that ceased operations in 2014.

AmerisourceBergen Specialty Group is scheduled to appear in federal court in Brooklyn for a plea hearing. A company spokeswoman said it related to its previously-disclosed agreement to plead guilty in connection with a subsidiary’s failure to register with the U.S. Food and Drug Administration.

Reporting by Nate Raymond in Boston; Editing by Chizu Nomiyama

Our Standards:The Thomson Reuters Trust Principles.

Source link